Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
Human glutaminyl cyclase (hQC) is drawing considerable attention and emerging as a potential druggable target for Alzheimer's disease (AD) due to its close involvement in the pathology of AD via the post-translational pyroglutamate modification of amyloid-β. A recent phase 2a study has shown pr...
Main Authors: | Daoyuan Chen, Qingxiu Chen, Xiaofei Qin, Peipei Tong, Liping Peng, Tao Zhang, Chunli Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2023.1209863/full |
Similar Items
-
Functions of glutaminyl cyclase and its isoform in diseases
by: Liu Yu’e, et al.
Published: (2023-01-01) -
Tetrahydroimidazo[4,5-<i>c</i>]pyridine-Based Inhibitors of <i>Porphyromonas gingivalis</i> Glutaminyl Cyclase
by: Daniel Ramsbeck, et al.
Published: (2021-11-01) -
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
by: Torsten Hoffmann, et al.
Published: (2021-10-01) -
Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer’s Disease and Its Tg2576 Mouse Model
by: Alexandra Bluhm, et al.
Published: (2022-07-01) -
Cellular response to β‐amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics
by: Haolin Zhang, et al.
Published: (2023-02-01)